Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

STEMBANCC

Financiado

Cerrado

Stem cells for Biological Assays of Novel drugs and prediCtive toxiCology (StemB...

Stem cells for Biological Assays of Novel drugs and prediCtive toxiCology (StemBANCC) StemBANCC, comprising internationally renowned investigators, is ideally positioned to deliver a unique European biorepository and drug discovery pipeline based upon human induced pluripotent stem cells (hiPSC). This unrivalled op... ver más

31/03/2018

ROCHE

55M€

Presupuesto del proyecto: 55M€

Líder del proyecto

F. HOFFMANNLA ROCHE AG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 36 Participantes

Financiación concedida El organismo FP6 notifico la concesión del proyecto el día 2018-03-31 No tenemos la información de la convocatoria

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

36 Participantes

ROCHE

Lider

LIU

N.D. | Participante

REGIONH

N.D. | Participante

Pfizer RD UK Limited

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

STEMBANCC Stem cells for Biological Assays of Novel drugs and prediCti... 55M€ Cerrado

DISEASEAVATARS Modeling Disease through Cell Reprogramming a Translational... 2M€ Cerrado

hiPSCmore Instrumented human stem cells to see more during high throug... 150K€ Cerrado

CENSUS Cell Based Models for Neurodegeneration Study and Use in Scr... 3M€ Cerrado

BIOCARD Deep BIOmodeling of human CARDiogenesis 2M€ Cerrado

DROPTECH Hanging Drop based automated and parallelized cell technolog... 5M€ Cerrado

Duración del proyecto: 65 meses Fecha Inicio: 2012-10-01
Fecha Fin: 2018-03-31

Líder del proyecto

F. HOFFMANNLA ROCHE AG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 55M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto StemBANCC, comprising internationally renowned investigators, is ideally positioned to deliver a unique European biorepository and drug discovery pipeline based upon human induced pluripotent stem cells (hiPSC). This unrivalled opportunity will address the pressing therapeutic need in neurodegeneration, neurodysfunction and diabetes. We have immediate access to richly phenotyped subjects with a wealth of clinical data. Furthermore our cohorts include genetic and genome data, allowing us to carefully select subjects for hiPSC based disease model development. This clinical-genetic stratification is essential to ensure that cellular models display disease and therapy relevant phenotypes. hiPSC reprogramming is undertaken by an internationally respected centre, providing robust, reliable and timely delivery of hiPSCs; ensures the biorepository only houses quality assured hiPSC lines; and reduces unwanted variability in assays. We have leading experts in hiPSC differentiation, providing protocols with over 99% efficiency in producing cortical excitatory neurons and cardiomyocytes, which following up-scaling will meet demands of high throughput assays. StemBANCC will deliver a comprehensive ‘omics’ dataset on over 1500 stem cell lines. This includes cells taken at different lineage stages, after therapeutic challenge, monogenic and complex variants, and with matched isogenic controls. The integration of this network/pathway data will define core etiopathological processes, therapeutic generality, reveal on- and off-target effects, allow candidate therapeutic repositioning and decouple tolerance and toxicity pathways. The large-scale integrated datasets then directly guide the disease specific targeted assays, designed to maximize utility in low and high- through compound screening programs. Assay development undertaken by the StemBANCC proposed central test facility thereby provides the final component of our hiPSC platform for drug discovery, development and safety.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores